Critical Path Institute Rebrands One of Its First Consortia to Highlight Focus on Alzheimer’s Disease Critical Path for Alzheimer’s Disease (CPAD) consortium’s refined, refocused mission centers on accelerating therapy developme
In Recognition of 10th Anniversary, Raymond Woosley and Janet Woodcock Address CPAD Consortium’s 2018 Annual Meeting and Regulatory Science Workshop At its 10th Annual Meeting and Regulatory Science Workshop, November 13, 2018, in Bethesda, MD, C-Path’s Critical Path for Alzhe
Drug Repurposing for Pandemic Innovation: Establishing an Effective and Efficient Ecosystem Effective treatments for both existing and emerging diseases may already be available on pharmacy shelves. Many approved drugs...
Sharing Data to Accelerate Medicines Development and Improve Neonatal Care: Data Standards and Harmonized Definitions
Critical Path Institute President/CEO Receives Award of Excellence Raymond L. Woosley, MD, PhD, President/CEO of Tucson-based Critical Path Institute (CPI), was recently presented with the prestigi
Podcast: Sharing Data to Improve Patient-Focused Outcomes Critical Path Institute’s Dr. Diane Stephenson joined host Alaina Webster to discuss the importance of data sharing to improve..
The Rare Disease Clinical Outcome Assessment Consortium: Aiming to Fulfill Unmet Drug Development Endpoint Measurement Needs Appropriate endpoint selection for rare disease trials is challenging. The Rare Disease Clinical Outcome Assessment (COA)....
Using Real World Data from CURE ID to Identify Drug Repurposing Opportunities in Mycology: Impact of Climate Change
Qualitative Development and Cognitive Evaluation of the Symptoms of Major Depressive Disorder (S-MDD), A Consortium-Developed Patient Reported Outcome Measure